Bolt Biotherapeutics, Inc. Common Stock (BOLT)

Price$4.56

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-17.98%

Price vs S&P 500 (4W)-2.35%

VGM Score51.42

Market Capitalization$8.76M

All Metrics

Book Value / Share (Quarterly)$10.32

P/TBV (Annual)0.20x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.33%

Cash Flow / Share (Quarterly)$-18.00

Price vs S&P 500 (YTD)-24.76%

Net Profit Margin (TTM)-455.15%

EPS (TTM)$-16.34

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-16.34

Revenue Growth (5Y)101.79%

EPS (Annual)$-17.85

ROI (Annual)-125.92%

Net Profit Margin (5Y Avg)-2299.04%

Cash / Share (Quarterly)$11.91

Revenue Growth QoQ (YoY)-97.87%

ROA (Last FY)-58.81%

Revenue Growth TTM (YoY)78.64%

EBITD / Share (TTM)$-16.85

ROE (5Y Avg)-77.69%

Operating Margin (TTM)-486.21%

Cash Flow / Share (Annual)$-20.79

P/B Ratio0.44x

P/B Ratio (Quarterly)0.39x

Net Income / Employee (Annual)$-1,451,100

EV / Revenue (TTM)-0.44x

ROA (TTM)-48.23%

EPS Incl Extra (Annual)$-17.85

Current Ratio (Annual)3.59x

Quick Ratio (Quarterly)3.14x

3-Month Avg Trading Volume0.03M

52-Week Price Return-23.49%

Revenue / Employee (TTM)$282,600

Tangible BV / Share (Quarterly)$3.38

P/S Ratio (Annual)1.14x

Asset Turnover (Annual)0.14x

52-Week High$7.35

Operating Margin (5Y Avg)-2253.29%

EPS Excl Extra (Annual)$-17.85

CapEx CAGR (5Y)-53.35%

26-Week Price Return-10.06%

Quick Ratio (Annual)3.40x

13-Week Price Return4.83%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.51x

Enterprise Value$-2.85M

Revenue / Share Growth (5Y)265.60%

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$334,600

Pretax Margin (Annual)-433.74%

Cash / Share (Annual)$14.32

3-Month Return Std Dev85.14%

Net Income / Employee (TTM)$-1,286,100

ROE (Last FY)-125.92%

EPS Basic Excl Extra (Annual)$-17.85

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-16.34

ROI (TTM)-100.90%

P/S Ratio (TTM)1.35x

Pretax Margin (5Y Avg)-2299.04%

Revenue / Share (Annual)$4.12

Tangible BV / Share (Annual)$4.54

Price vs S&P 500 (52W)-47.86%

Year-to-Date Return-16.61%

5-Day Price Return-14.12%

EPS Normalized (Annual)$-17.85

ROA (5Y Avg)-47.24%

Net Profit Margin (Annual)-433.74%

Month-to-Date Return-13.14%

Cash Flow / Share (TTM)$-1.84

EBITD / Share (Annual)$-18.62

Operating Margin (Annual)-469.30%

ROI (5Y Avg)-77.69%

EPS Basic Excl Extra (TTM)$-16.34

P/TBV (Quarterly)0.27x

P/B Ratio (Annual)0.40x

Pretax Margin (TTM)-455.15%

Book Value / Share (Annual)$13.80

Price vs S&P 500 (13W)-3.43%

Beta1.18x

Revenue / Share (TTM)$3.87

ROE (TTM)-100.90%

52-Week Low$3.91

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-4.31est. -2.91

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.82

3.90

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BOLTBolt Biotherapeutics, Inc. Common Stock	—	C	C	$4.56
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that activate both innate and adaptive immune responses. The company's proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating payloads, leveraging deep expertise in myeloid biology. Its pipeline includes three candidates: BDC-1001, BDC-3042, and a next-generation ISAC therapeutic.